Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;52(7):2673-6.
doi: 10.1128/AAC.01596-07. Epub 2008 Apr 28.

Pharmacokinetics and tissue distribution of anidulafungin in rats

Affiliations

Pharmacokinetics and tissue distribution of anidulafungin in rats

Bharat Damle et al. Antimicrob Agents Chemother. 2008 Jul.

Abstract

This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 min, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Molecular structure of [14C]anidulafungin, in which the position of the 14C radiolabel is indicated by an asterisk.
FIG. 2.
FIG. 2.
Study 1. Mean (n = 3) concentration-versus-time profile for anidulafungin (parent drug) in plasma (ng/ml) and in key tissues (ng/g) following a single intravenous bolus dose of 5 mg/kg [14C]anidulafungin in male F344 rats.
FIG. 3.
FIG. 3.
Study 1. Tissue/plasma ratio of AUC0-∞ of anidulafungin (parent drug) following a single intravenous bolus dose of 5 mg/kg [14C]anidulafungin in male F344 rats.
FIG. 4.
FIG. 4.
Study 1. Mean (n = 3) concentration-versus-time profile of drug-derived radioactivity (ng eq/g) in plasma and key tissues following a single intravenous bolus dose of 5 mg/kg [14C]anidulafungin in male F344 rats.

References

    1. Dodds Ashley, E. S., R. Lewis, J. S. Lewis, C. Martin, and D. Andes. 2006. Pharmacology of systemic antifungal agents. Clin. Infect. Dis. 43:S28-S39.
    1. Dowell, J. A., F. Pu, J. Lee, M. Stogniew, D. Krause, and T. Henkel. 2003. A clinical mass balance study of anidulafungin showing complete fecal elimination. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1576.
    1. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956. - PMC - PubMed
    1. Gumbo, T., G. L. Drusano, W. Liu, R. W. Kulawy, C. Fregeau, V. Hsu, and A. Louie. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51:968-974. - PMC - PubMed
    1. Gumbo, T., G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie. 2006. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50:3695-3700. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources